MakroCare, an international Drug Development and Commercialization services firm, and LSK Global, a Korean CRO headquartered in Seoul, recently announced the signing of an alliance agreement. The agreement means the two companies can offer their wide range of services to pharmaceutical, biotechnology and device companies in key territories in Asia.

LSK Global provides clinical services for phase I/II/ III studies. LSK Global was established in 2000. Talking about the alliance, Ashok Ghone, Ph.D. (VP, Global Services) mentioned that MakroCare and LSK Global operate in key strategic regions of USA & Asia and the collaborative relationship between two companies provides opportunity, now that MakroCare can extend support, to their potential & existing customers that need services in Korea, utilizing LSK’s local know-how. LSK Global will be utilizing MakroCare’s USA and other Asian region strengths effectively.

MakroCare, established in 1996, is an international Drug Development and Commercialization services firm that is dedicated to support pharma, biotech and medical device companies to achieve high-level of performance. MakroCare has 5 divisions – Consulting, CRO, SMO, Informatics, and Commz to support various aspects of product life cycle management. MakroCare has teams positioned worldwide in these divisions supporting several services including management consulting, regulatory affairs, risk management, study feasibility, clinical trial management (early to late phase), biometrics (CDM, EDC, biostatistics, SAS programming, medical writing), QA audits, safety/PV, site management, patient recruitment and retention, and informatics.